Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo- and Active Comparator-controlled, Crossover Trial to Examine the Effect of Multiple Doses of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy Subject

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Placebo- and Active Comparator-controlled, Crossover Trial to Examine the Effect of Multiple Doses of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy Subject

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jun 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Darigabat (Primary) ; Alprazolam
  • Indications Anxiety disorders; Epilepsy; Panic disorder; Seizures
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Cerevel Therapeutics

    • Most Recent Events

    • 27 Apr 2023 Results presented at the 75th Annual Meeting of the American Academy of Neurology 2023
    • 15 Feb 2022 According to Cerevel Therapeutics media release, the company will host a conference call and webcast to discuss the results from this trial.
    • 15 Feb 2022 Primary endpoint (PSL-IV score) has been met, according to a Cerevel Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top